Search

Displaying results 2011 - 2020 of 10000 in total
  1. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Polio Salk "Merieux" - Fertigspritze
  2. Target

    Nuclear factor NF-kappa-B complex

    go.drugbank.com/bio_entities/BE0009554
    TargetHumans

    Essential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. … The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity

    Synonyms: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  3. Drug

    Vanglusagene ensiparvovec

    go.drugbank.com/drugs/DB17675
    Investigational

    Synonyms: RG-6359, recombinant adeno-associated viral (AAV) vector that contains a bio-engineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of human acid a-glucosidase
  4. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.

    Categories: Compounds used in a research, industrial, or household setting, Drugs for Constipation
  5. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic

  6. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who

  7. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients

  8. Drug

    Selenomethionine

    go.drugbank.com/drugs/DB11142
    ApprovedInvestigational

    In comparison to selenite, which is the inorganic form of selenium, the organic form of selenomethionine is more readily absorbed in the human body. … Selenomethionin is used in biochemical laboratories where its incorporation into proteins that need to be visualized enhances the performance of X-ray crystallography.

    Mixtures: Vital-D Rx, BiO-LiFE Anti-FR+Selenium Tablets
  9. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Polio Salk "Merieux" - FertigspritzeSynonyms: Inactivated poliovirus type II